hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06315231, orgStudyIdInfo id: SIM0308-02-Y-2-201, briefTitle: Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-31, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-05-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Simcere Pharmaceutical Co., Ltd, class: OTHER, descriptionModule briefSummary: This is a multicenter, randomized, double-blind, placebo-controlled, exploratory Phase II clinical trial.The goal of this clinical trial is to assess the safety and efficacy of edaravone dexborneol sublingual tablets for post-stroke cognitive impairment in patients with acute ischemic stroke.Participants will be required to receive 12 weeks treatment of edaravone dexborneol sublingual tablets or placebo during this study. The safety and efficacy endpoints will be compared in the patients with edaravone dexborneol sublingual tablets or placebo., conditionsModule conditions: Post-stroke Cognitive Impairment, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Edaravone dexborneol sublingual tablet, interventions name: Placebo, outcomesModule primaryOutcomes measure: Adverse Events, primaryOutcomes measure: Number of discontinuation/withdrawal patients, primaryOutcomes measure: The changes of the Vascular Dementia Assessment Scale-cognitive subscale (VaDAS-Cog) scores., secondaryOutcomes measure: The incidence of Post Stroke Cognitive Impairment（PSCI ）in each group, secondaryOutcomes measure: The changes of Mini-Mental State Examination (MMSE) score, secondaryOutcomes measure: The changes of Montreal Cognitive Assessment (MoCA) scale, secondaryOutcomes measure: The changes of MoCA subscales, secondaryOutcomes measure: Modified Rankin Scale (mRS) scores, secondaryOutcomes measure: The changes of National Institutes of Health Stroke Scale, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of USTC Anhui Provincial Hospital, city: Hefei, state: Anhui, country: China, contacts name: Jiong Shi, Doctor, role: CONTACT, email: Jshi2022@ustc.edu.cn, geoPoint lat: 31.86389, lon: 117.28083, locations facility: The First Hospital of Jilin University, city: Changchun, state: Jilin, country: China, contacts name: Li Sun, role: CONTACT, email: sunli99@jlu.edu.cn, geoPoint lat: 43.88, lon: 125.32278, locations facility: The First People's Hospital of Huzhou, city: Huzhou, state: Zhejiang, country: China, contacts name: Ru Sun, Doctor, role: CONTACT, email: sunjin2010@tom.com, geoPoint lat: 30.8703, lon: 120.0933, hasResults: False
protocolSection identificationModule nctId: NCT06315218, orgStudyIdInfo id: Pro2023000968, briefTitle: Examining the Health Effects of iTHRIVE 365 Among Black Same Gender Loving Men, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2028-04, completionDateStruct date: 2028-04, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Rutgers, The State University of New Jersey, class: OTHER, collaborators name: Positive Impact Health Centers, collaborators name: George Washington University, collaborators name: Carnegie Mellon University, collaborators name: Emory University, collaborators name: Columbia University, collaborators name: Arizona State University, collaborators name: THRIVE Social Services Inc, descriptionModule briefSummary: This research study aims to test the effectiveness, reach, and maintenance over time of the iTHRIVE 365 intervention for Black same gender loving men (SGLM) living with HIV. iTHRIVE 365 is a SGLM community-developed multicomponent mHealth intervention that aims to: 1) Support daily health promotion via HIV and psychological health education and health maintenance reminders; 2) Foster positive social connections among SGLM via online moderated forums, interpersonal chats, and community calendars; 3) Connect clients to SGLM-affirming healthcare, including HIV treatment and mental healthcare; 4) Provide resources for housing, transportation, and other economic empowerment., conditionsModule conditions: Sexual and Gender Minorities, conditions: Social Stigma, conditions: Medication Adherence, conditions: Depressive Symptoms, conditions: Anxiety Symptoms, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 350, type: ESTIMATED, armsInterventionsModule interventions name: iTHRIVE 365 HIV care intervention, outcomesModule primaryOutcomes measure: Antiretroviral (ART) Medication Use, primaryOutcomes measure: ART adherence-Long Lag Assessments, secondaryOutcomes measure: Daily Diary Substance Use, secondaryOutcomes measure: Substance Use-Long Lag Assessments, secondaryOutcomes measure: Depressive Symptoms, secondaryOutcomes measure: Depressive Symptoms-Long Lag, secondaryOutcomes measure: Anxiety Symptoms, secondaryOutcomes measure: Anxiety Symptoms-Long Lag, secondaryOutcomes measure: Emotion Regulation Emotion Regulation, secondaryOutcomes measure: Emotion Regulation-Long Lag Assessments, secondaryOutcomes measure: COPE, secondaryOutcomes measure: COPE-Long Lag Assessments, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06315205, orgStudyIdInfo id: ROV-LEBE-2023-01, secondaryIdInfos id: 2023-503948-13, type: EUDRACT_NUMBER, briefTitle: Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women, acronym: LEILA-1, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-26, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2025-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Rovi Pharmaceuticals Laboratories, class: INDUSTRY, descriptionModule briefSummary: This is a Phase I, open label, sequential, single ascending dose (SAD) study to evaluate the pharmacokinetic (PK), safety, and tolerability of Letrozole LEBE in healthy post-menopausal women., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Letrozole LEBE 75 mg, interventions name: Letrozole LEBE 150 mg, interventions name: Letrozole LEBE 225 mg, outcomesModule primaryOutcomes measure: λz, primaryOutcomes measure: Cmax, primaryOutcomes measure: Clast, primaryOutcomes measure: tmax, primaryOutcomes measure: tlag, primaryOutcomes measure: t1/2, primaryOutcomes measure: AUC∞, primaryOutcomes measure: AUClast, secondaryOutcomes measure: E1, secondaryOutcomes measure: SE1, secondaryOutcomes measure: E2, secondaryOutcomes measure: λz, secondaryOutcomes measure: Cav, secondaryOutcomes measure: Cmin, ss, secondaryOutcomes measure: Cmax,ss, secondaryOutcomes measure: tmax, secondaryOutcomes measure: t1/2, secondaryOutcomes measure: AUCτ, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Investigational Site number CZ-01, status: RECRUITING, city: Praha, country: Czechia, geoPoint lat: 50.08804, lon: 14.42076, hasResults: False
protocolSection identificationModule nctId: NCT06315179, orgStudyIdInfo id: STUDY00004616, briefTitle: Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE), acronym: STRIDE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2028-01, completionDateStruct date: 2030-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Seattle Children's Hospital, class: OTHER, collaborators name: Allen Institute, descriptionModule briefSummary: This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation and a control cohort of pediatric patients with disorders of the brain-gut interactions (DBGI) with no detectable gut inflammation., conditionsModule conditions: Inflammatory Bowel Diseases, conditions: Crohn Disease, conditions: Ulcerative Colitis, conditions: Indeterminate Colitis, conditions: Functional Abdominal Pain Syndrome, conditions: Functional Bowel Disorder, conditions: Esophageal Diseases, conditions: Gastroduodenal Disorder, conditions: Bowel Dysfunction, conditions: Gallbladder Diseases, conditions: Sphincter of Oddi Dysfunction, conditions: Anorectal Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Esophagogastroduodenoscopy (EGD) with biopsy, interventions name: Colonoscopy w/ biopsy, outcomesModule primaryOutcomes measure: Bio-repository sample collection for spatial transcriptomics, secondaryOutcomes measure: Paris Classification of Crohn's Disease, secondaryOutcomes measure: Montreal Classification of Crohn's disease, secondaryOutcomes measure: Paris Classification of Ulcerative Colitis/Indeterminate Colitis, secondaryOutcomes measure: Montreal Classification of Ulcerative Colitis/Indeterminate Colitis, secondaryOutcomes measure: Disorder of Gut-Brain Interaction classification, secondaryOutcomes measure: Physician's Global Assessment (PGA), eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 21 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Seattle Children's Hospital, city: Seattle, state: Washington, zip: 98105, country: United States, contacts name: Mason E Nuding, role: CONTACT, phone: 206-987-0055, email: mason.nuding@seattlechildrens.org, contacts name: Clinical Research Coordinator, role: CONTACT, phone: 206-987-2521, email: giresearch@seattlechidlrens.org, contacts name: Hengqi Zheng, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 47.60621, lon: -122.33207, hasResults: False
protocolSection identificationModule nctId: NCT06315166, orgStudyIdInfo id: CIP-PLG_CLINICAL-22-04, briefTitle: Study on Using Radiofrequency to Treat Moderate to Severe Acne, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Pollogen, class: INDUSTRY, collaborators name: Lumenis Be Ltd., descriptionModule briefSummary: Evaluation of the safety and efficacy of fractional radiofrequency for the treatment of moderate to severe acne vulgaris., conditionsModule conditions: Moderate to Severe Acne Vulgaris, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: triLift/Legend Pro+ Fractional RF System, outcomesModule primaryOutcomes measure: Evaluate the Efficacy of Fractional RF for the Treatment of Moderate to Severe Acne Vulgaris, secondaryOutcomes measure: Overall Improvement of Acne, secondaryOutcomes measure: Subjective Satisfaction with the Treatment Results, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 25 Years, stdAges: ADULT, contactsLocationsModule locations facility: Cosmedic Dermatology (CosmedicDerm), status: RECRUITING, city: Grosse Pointe, state: Michigan, zip: 48230, country: United States, contacts name: Shauna Ryder Diggs, MD, role: CONTACT, phone: 313-882-5777, email: hello@drshaunadiggs.com, contacts name: Jamila Ammary, role: CONTACT, phone: +1-313-882-5777, email: hello@drshaunadiggs.com, contacts name: Shauna Ryder Diggs, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.38615, lon: -82.91186, hasResults: False
protocolSection identificationModule nctId: NCT06315153, orgStudyIdInfo id: KS2023077-1, briefTitle: Comprehensive Assessment of Atherosclerotic Ischemic Stroke Risk and Development of a Prediction Model, acronym: CAIS-pre, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-01-03, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2026-04-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Xuanwu Hospital, Beijing, class: OTHER, collaborators name: The First Hospital of Jilin University, descriptionModule briefSummary: This observational study was designed for the assessment of plaque vulnerability in patients with carotid atherosclerotic stenosis and the development of predictive models for the occurrence and recurrence of atherosclerotic ischemic stroke.The objectives of the study were as follows: first, to integrate the degree of carotid stenosis and plaque characteristics assessed by vascular ultrasound for a comprehensive assessment of plaque vulnerability; second, to develop an assessment tool for the risk of future ischemic stroke in patients with asymptomatic carotid stenosis by combining vascular risk factors, serologic markers, carotid ultrasound characteristics, and contrast-enhanced ultrasonographic parameters; and third, to incorporate vascular ultrasound parameters into existing predictive models of ischemic stroke recurrence risk to develop a risk assessment tool for atherosclerotic ischemic stroke.The main questions it aims to answer are:* How to screen high-risk patients and those eligible for revascularization from asymptomatic carotid stenosis patients for primary prevention of stroke.* How to improve the prediction accuracy of atherosclerotic ischemic stroke based on existing prediction models for secondary prevention of stroke., conditionsModule conditions: Carotid Stenosis, conditions: Ischemic Stroke, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: The occurrence of ischemic stroke, primaryOutcomes measure: The recurrence of ischemic stroke, eligibilityModule sex: ALL, minimumAge: 40 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The first hospital of Jilin university, city: Changchun, state: Jilin, zip: 130021, country: China, geoPoint lat: 43.88, lon: 125.32278, locations facility: Xuanwu Hospital, Capital Medical University, city: Beijing, zip: 100053, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06315101, orgStudyIdInfo id: K-2023-092, briefTitle: Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Guangzhou University of Chinese Medicine, class: OTHER, descriptionModule briefSummary: This study aims to assess the effectiveness and safety of lenvatinib plus Chinese Herbal Medicine (CHM) for patients with uHCC in China., conditionsModule conditions: Unresectable Hepatocellular Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 142, type: ACTUAL, armsInterventionsModule interventions name: Chinese Herbal Medicine, outcomesModule primaryOutcomes measure: Efficacy outcomes, primaryOutcomes measure: Survival analysis, primaryOutcomes measure: Survival analysis, secondaryOutcomes measure: Adverse Events assessment, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: the First Affiliated Hospital of Guangzhou University of Chinese Medicine, city: Guangzhou, state: Guangdong, zip: 510407, country: China, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06315062, orgStudyIdInfo id: CEC-UNIBE-07-2023, briefTitle: Efficacy of Rezum® in Reducing Prostate Volume, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-01-01, primaryCompletionDateStruct date: 2022-12-31, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Urología Costa Rica, class: OTHER, descriptionModule briefSummary: This study aimed to assess the efficacy of Rezum® water vapor therapy in reducing prostate volume in patients aged 40 years or older with Benign Prostate Hyperplasia (BPH) at UNIBE Hospital in Costa Rica. A retrospective analysis will be conducted on 289 patient records, focusing on prostate volume, International Prostate Symptom Score (IPSS), and urinary flow rate. Statistical analyses included two-sample mean comparisons, effect size estimation, and linear regression., conditionsModule conditions: Benign Hyperplasia of Prostate, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 289, type: ACTUAL, outcomesModule primaryOutcomes measure: Prostate volume, secondaryOutcomes measure: International Prostate Symptome Score, secondaryOutcomes measure: Urinary flow rate, eligibilityModule sex: MALE, minimumAge: 40 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital UNIBE, city: San José, zip: 11301, country: Costa Rica, geoPoint lat: 9.93333, lon: -84.08333, hasResults: False
protocolSection identificationModule nctId: NCT06315049, orgStudyIdInfo id: 2023-ENFPOD-2621979, briefTitle: Music Therapy to Reduce Anxiety in Community-Dwelling Individuals With Severe Mental Illness, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-06-26, primaryCompletionDateStruct date: 2023-07-31, completionDateStruct date: 2023-07-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Universitat Politècnica de València, class: OTHER, collaborators name: University of Valencia, descriptionModule briefSummary: This study aims to measure the effectiveness of the Music Therapy nursing intervention in reducing anxiety in outpatients diagnosed with severe mental illness (SMI) (bipolar disorder and schizophrenia). The intervention was structured over five weeks (ten 1-hour sessions, twice weekly). Objective measures (blood pressure, heart rate, and respiratory rate) and subjective measures (anxiety response and the subjective perception of relaxation) were taken before and after every session., conditionsModule conditions: Severe Mental Disorder, conditions: Schizophrenia, conditions: Bipolar Disorder, conditions: Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 14, type: ACTUAL, armsInterventionsModule interventions name: Music therapy, outcomesModule primaryOutcomes measure: IDARE test, primaryOutcomes measure: SBP, primaryOutcomes measure: DBP, primaryOutcomes measure: HR, primaryOutcomes measure: RR, eligibilityModule sex: ALL, minimumAge: 35 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Universitat Politècnica de València, city: Valencia, zip: 46022, country: Spain, geoPoint lat: 39.46975, lon: -0.37739, hasResults: False
protocolSection identificationModule nctId: NCT06315023, orgStudyIdInfo id: CP-0029, briefTitle: The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry), acronym: PTAB1, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2023-10-06, primaryCompletionDateStruct date: 2028-06-07, completionDateStruct date: 2032-06-07, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Endologix, class: INDUSTRY, collaborators name: Fivos, collaborators name: Massachusetts General Hospital, collaborators name: Society for Vascular Surgery Patient Safety Organization, descriptionModule briefSummary: The purpose of this post-market surveillance study will be to evaluate the real-world use of the DETOUR System in treated patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis \> 70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments., conditionsModule conditions: Peripheral Arterial Disease, conditions: Symptomatic Femoropopliteal Lesions, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 450, type: ESTIMATED, armsInterventionsModule interventions name: DETOUR System, outcomesModule primaryOutcomes measure: Freedom from CD-TLR, primaryOutcomes measure: Freedom from MAE, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: NYU Langone Medical Center, city: New York, state: New York, zip: 10016, country: United States, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False